| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| September 21st, 2009 | 7 | No |
Popular Name: D-Cycloserine D-Cycloserine
(4R)-4-amino-1,2-oxazolidin-3-one
(4R)-4-Amino-3-isoxazolidinone
(4R)-4-aminoisoxazolidin-3-one
(R)-(+)-4-Amino-3-isoxazolidinone
(R)-3-Isoxazolidinone, 4-amino-
(R)-4-Amino-isoxazolidin-3-one
3-Isoxazolidinone, 4-amino- (9CI)
3-Isoxazolidinone, 4-amino-, (+)-
3-Isoxazolidinone, 4-amino-, (+)- (8CI)
3-Isoxazolidinone, 4-amino-, (4R)- (9CI)
3-Isoxazolidinone, 4-amino-, (R)
3-Isoxazolidinone, 4-amino-, (R)-
3-Isoxazolidinone, 4-amino-, D
3-Isoxazolidinone, 4-amino-, d-
4-27-00-05549 (Beilstein Handbook Reference)
68-41-7; C08057; Cycloserine; D-Cycloserine
68-41-7; CPD000058313; D-CYCLOSERINE; SAM002264599
68-41-7; Cycloserine (JP16/USP/INN); D00877; Seromycin (TN)
cicloserina; cycloserine; cycloserinum
CPD000058313; Cycloserine; D-CYCLOSERINE; SAM002264599
CPD000058313; D-CYCLOSERINE; 68-41-7
D-4-Amino-3-isossazolidone [Italian]
D-Cycloserine, Streptomyces orchidaceus
FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | -1.71 | -5.16 | -42.02 | 3 | 4 | 0 | 72 | 102.093 | 0 | ↓ |
| Ref Reference (pH 7) | -1.71 | -6.26 | -6.38 | 3 | 4 | 0 | 68 | 102.093 | 0 | ↓ |
| Hi High (pH 8-9.5) | -1.71 | -5.45 | -42.88 | 2 | 4 | -1 | 71 | 101.085 | 0 | ↓ |
| Mid Mid (pH 6-8) | -1.90 | -3.9 | -7.02 | 3 | 4 | 0 | 64 | 102.093 | 0 | ↓ |
| Lo Low (pH 4.5-6) | -1.71 | -5.95 | -48.42 | 4 | 4 | 1 | 69 | 103.101 | 0 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| biological_source | Prod. by Streptomyces garyphalus, Streptomyces orchidaceus, Streptomyces lavendulae and Streptomyces nagasakiensis | ZereneX Building Blocks |
| mechanism | . | ZereneX Building Blocks |
| MP | 137 | TCI |
| Melting_Point | 137? dec. | Alfa-Aesar |
| Melting_Point | 137° dec. | Alfa-Aesar |
| MP | 138-141° | Oakwood Chemical |
| MP | 147 - 149 | Enamine Building Blocks |
| M.P | 147 °C | Indofine |
| MP | 147...149 | Enamine Building Blocks |
| UniProt Database Links | 2B11_HUMAN; 2B13_HUMAN; 2B14_HUMAN; 2B17_HUMAN; 2B18_HUMAN; 2B19_HUMAN; 2B1A_HUMAN; 2B1B_HUMAN; 2B1C_HUMAN; 2B1D_HUMAN; 2B1E_HUMAN; 2B1F_HUMAN; 2B1G_HUMAN; ALR_GEOSE; ALR_MYCAV; ALR_MYCSM; ALR_MYCTU; CD209_CHLAE; CD209_GORGO; CD209_HUMAN; CD209_HYLLA; CD2 | ChEBI |
| ALOGPS_SOLUBILITY | 8.77e+02 g/l | DrugBank-approved |
| purity | 9.500000000000000e+001 | Enamine Building Blocks Enamine Building Blocks |
| Purity | 95% | Fluorochem |
| Purity | 95+% | Matrix Scientific |
| Purity | 98% | Fluorochem |
| UniProt Database Links | ALR_MYCSM; DCSA_STRLA; DCSB_STRLA; DCSC_STRLA; DCSD_STRLA; DCSE_STRLA; DCSG_STRLA; LAAA_PSEAZ; LAAA_PSEFS; PAND_ECOLI; PAND_ECOLW; RSAM_PSESP; TCAA_STAA9 | ChEBI |
| mechanism | Antagonizes the role of D-alanine in bacterial cell-wall-synthesis | IBScreen Bioactives |
| therap | antibacterial (tuberculostatic) | MicroSource Spectrum |
| Indications | antibacterial, tuberculosis | KeyOrganics Bioactives |
| Target | Antifection | Selleck Chemicals |
| PUBCHEM_PATENT_ID | EP0948616A2; US5925354; WO1998018917A2 | IBM Patent Data |
| Patent Database Links | EP1588702; EP1685843; EP1884520; US2003082830; US2003105066; US2005020659; US2006128963; US2007202051; US2007207222; US2007265319; US2007269539; WO2005009950; WO2005066135; WO2005066143; WO2006113140; WO2007089745; WO2007103687; WO2007109180; WO2007117509 | ChEBI |
| Therapy | Excitatory amino acid; partial agonist at the glycine modulatory site of the NMDA glutamate receptor | SMDC Pharmakon |
| mechanism | Inhibits cell-wall-synthesis in: Mycobacterium tuberculosis | IBScreen Bioactives IBScreen Bioactives |
| Warnings | IRRITANT | Matrix Scientific |
| PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : LightBiologicals; NCC_SUPPLIER_STRUCTURE_ID : C-3119 | NIH Clinical Collection via PubChem |
| Target | Others | Selleck Chemicals |
| PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: LightBiologicals; SUPPLIER_STRUCTURE_ID: C-3119 | NIH Clinical Collection via PubChem |
| biological_use | Shows antibiotic activity primarily against mycobacteria | IBScreen Bioactives IBScreen Bioactives |
| mechanism | Susceptible strains of gram-negative bacteria | IBScreen Bioactives |
| mechanism | Susceptible strains of gram-positive bacteria | IBScreen Bioactives |
| biological_use | Tuberculostatic | IBScreen Bioactives |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| NMDZ1-4-E | Glutamate (NMDA) Receptor Subunit Zeta 1 (cluster #4 Of 6), Eukaryotic | Eukaryotes | 7370 | 1.03 | Binding ≤ 10μM |
| Z104302-3-O | Glutamate NMDA Receptor (cluster #3 Of 7), Other | Other | 2300 | 1.13 | Binding ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| NMDZ1_RAT | P35439 | Glutamate (NMDA) Receptor Subunit Zeta 1, Rat | 7370 | 1.03 | Binding ≤ 10μM |
| Z104302 | Z104302 | Glutamate NMDA Receptor | 2300 | 1.13 | Binding ≤ 10μM |
| Description | Species |
|---|---|
| CREB phosphorylation through the activation of CaMKII | |
| EPHB-mediated forward signaling | |
| Ras activation uopn Ca2+ infux through NMDA receptor | |
| Unblocking of NMDA receptor, glutamate binding and activation |
